PT2403845E - Processo melhorado - Google Patents

Processo melhorado Download PDF

Info

Publication number
PT2403845E
PT2403845E PT107079501T PT10707950T PT2403845E PT 2403845 E PT2403845 E PT 2403845E PT 107079501 T PT107079501 T PT 107079501T PT 10707950 T PT10707950 T PT 10707950T PT 2403845 E PT2403845 E PT 2403845E
Authority
PT
Portugal
Prior art keywords
improved process
improved
Prior art date
Application number
PT107079501T
Other languages
English (en)
Inventor
Vinayak Govind Gore
Vinay Kumar Shukla
Shreyas Shrikant Bhandari
Suresh Hasbe
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Publication of PT2403845E publication Critical patent/PT2403845E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Optical Communication System (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
PT107079501T 2009-03-02 2010-03-01 Processo melhorado PT2403845E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN383KO2009 2009-03-02
IN463KO2009 2009-03-16

Publications (1)

Publication Number Publication Date
PT2403845E true PT2403845E (pt) 2014-08-04

Family

ID=54290149

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107079501T PT2403845E (pt) 2009-03-02 2010-03-01 Processo melhorado

Country Status (16)

Country Link
US (1) US8946265B2 (pt)
EP (1) EP2403845B1 (pt)
JP (1) JP5727944B2 (pt)
CN (1) CN102414196A (pt)
AU (1) AU2010220204B2 (pt)
CA (1) CA2753241C (pt)
CY (1) CY1115376T1 (pt)
DK (1) DK2403845T3 (pt)
ES (1) ES2487215T3 (pt)
HR (1) HRP20140686T1 (pt)
NZ (1) NZ595492A (pt)
PL (1) PL2403845T3 (pt)
PT (1) PT2403845E (pt)
SI (1) SI2403845T1 (pt)
SM (1) SMT201400100B (pt)
WO (1) WO2010100476A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
CA2793312C (en) * 2010-03-08 2016-06-14 Natco Pharma Limited Anhydrous lenalidomide form-i
US9044479B2 (en) 2010-06-16 2015-06-02 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
CA2842316A1 (en) 2011-07-19 2013-01-24 Amplio Pharma, Llc Urea cocrystal of 3-(4-amin0-1-0x0-1,3 dihydro-isoindol-2-yl)­piperidine-2,6-dione
CN102838586A (zh) * 2012-09-20 2012-12-26 重庆泰濠制药有限公司 一种制备来那度胺的方法
AU2014249456B2 (en) 2013-03-13 2018-08-09 IRR, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
EP3308835B1 (en) 2013-03-13 2020-01-01 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CN105263579B (zh) 2013-03-13 2020-01-10 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗血管炎中的用途
US9808450B2 (en) 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103601717A (zh) * 2013-10-09 2014-02-26 湖南华腾制药有限公司 一种来那度胺的新型制备方法
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
WO2014155371A2 (en) * 2014-04-26 2014-10-02 Shilpa Medicare Limited Crystalline lenalidomide process
US10392364B2 (en) 2014-08-11 2019-08-27 Avra Laboratories Pvt. Ltd. Process for synthesis of lenalidomide
WO2016026785A1 (en) * 2014-08-19 2016-02-25 Synthon B.V. Process for making crystalline form a of lenalidomide
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
EP3393457A1 (en) 2015-12-22 2018-10-31 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
KR20200092945A (ko) * 2017-09-27 2020-08-04 바이오콘 리미티드 레날리도마이드의 결정형
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN111196800B (zh) * 2018-11-19 2022-10-11 欣凯医药化工中间体(上海)有限公司 一种制备来那度胺的方法
WO2022144924A1 (en) * 2021-01-04 2022-07-07 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2579291C (en) 2004-09-03 2011-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
EP2136896B1 (en) 2007-04-16 2015-01-21 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating n-glycans
US20110041589A1 (en) 2007-12-14 2011-02-24 Generics [Uk] Limited New hpcl method
KR20100124710A (ko) 2008-03-11 2010-11-29 닥터 레디스 레보러터리즈 리미티드 레날리도미드의 제조
AU2009321374A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide

Also Published As

Publication number Publication date
WO2010100476A3 (en) 2011-06-16
DK2403845T3 (da) 2014-08-04
EP2403845A2 (en) 2012-01-11
JP5727944B2 (ja) 2015-06-03
ES2487215T3 (es) 2014-08-20
SI2403845T1 (sl) 2014-09-30
US8946265B2 (en) 2015-02-03
CA2753241C (en) 2015-06-16
PL2403845T3 (pl) 2014-09-30
SMT201400100B (it) 2014-11-10
JP2012519207A (ja) 2012-08-23
CY1115376T1 (el) 2017-01-04
CA2753241A1 (en) 2010-09-10
AU2010220204A1 (en) 2011-10-20
WO2010100476A2 (en) 2010-09-10
NZ595492A (en) 2013-07-26
US20120071509A1 (en) 2012-03-22
AU2010220204B2 (en) 2015-10-08
CN102414196A (zh) 2012-04-11
EP2403845B1 (en) 2014-04-30
HRP20140686T1 (hr) 2014-09-26

Similar Documents

Publication Publication Date Title
GB0918069D0 (en) Process
SI2403845T1 (sl) Izboljšani postopek
GB0901254D0 (en) Process
GB0919117D0 (en) Process
GB0919385D0 (en) Process
GB201011823D0 (en) Process
GB0907879D0 (en) Process
GB0918830D0 (en) Process
GB0905998D0 (en) Process
GB0914338D0 (en) Improved process
GB0906191D0 (en) Process
GB0914500D0 (en) Process
GB0901817D0 (en) Process
GB0914572D0 (en) Process
GB0912254D0 (en) Process
ZA201108937B (en) Process
GB0918613D0 (en) Process
GB0915106D0 (en) Process
GB0913318D0 (en) Process
GB0902286D0 (en) Process
GB0901816D0 (en) Process
GB0906031D0 (en) Process
GB0903956D0 (en) Process
GB0901822D0 (en) Process
GB0915627D0 (en) Process